CT灌注成像作为胰腺导管腺癌常规分期与再分期中的潜在生物标志物
前瞻性研究将CT灌注采集融入70例PDAC患者基线多期增强CT,其中28例初治患者纳入分析。以RECIST 1.1分为应答者(18例)与非应答者,发现非应答者肿瘤最大ROI的BF、PS、BV变异系数更高,肿瘤中心BV均值更低,且与不良应答相关。
要点
- 基线肿瘤灌注异质性高(BF、PS、BV变异系数大)提示新辅助治疗应答不佳。
- 肿瘤中心BV均值低与非应答相关(OR 0.28每1-SD增加)。
- 单次注射对比剂即可将灌注采集融入常规多期分期CT。
核心结论
- PDAC患者接受新辅助治疗时,较低且更不均一的灌注参数与不良治疗应答相关。
研究设计与样本
- 前瞻性研究,70例PDAC患者基线多期分期CT中融入CT灌注采集,28例初治患者纳入分析。
- 灌注采集在对比剂注射后5–42.5秒进行,随后行实质期和门静脉期,采用去卷积算法计算BF、BV、PS。
- 以RECIST 1.1将患者分为应答者与非应答者,保留AUC≥0.70的灌注变量,用逻辑回归评估基线灌注变量与应答的关联。
诊断标准与关键数值
- 应答者18例、非应答者10例(共28例),按RECIST 1.1判定应答。
- 非应答者肿瘤最大ROI的BF变异系数中位数0.91 vs 应答者0.51,每1-SD增加OR 6.8,P=0.047。
- 非应答者PS变异系数中位数1.6 vs 0.68,每1-SD增加OR 3.9,P=0.047。
- 非应答者BV变异系数中位数0.75 vs 0.54,每1-SD增加OR 4.0,P=0.047。
- 非应答者肿瘤中心BV均值中位数0.74 vs 2.9 ml/100 g,每1-SD增加OR 0.28,P=0.047。
临床应用与阅片要点
- 在常规分期CT中单次注射对比剂即可整合灌注采集,无需额外注射。
- 阅片时可关注肿瘤最大ROI内BF、PS、BV的变异系数及肿瘤中心BV均值,辅助预判新辅助治疗应答。
- 灌注参数定量信息可能帮助筛选手术候选者并预测结局。
局限性
- 仅28例初治患者纳入分析,样本量小。
- 单中心前瞻性研究,结论需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the significance of CT perfusion parameters predicting response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma (PDAC).
MATERIALS AND METHODS: Seventy patients with PDAC prospectively had CT perfusion acquisition incorporated into baseline multiphase staging CT. Twenty-eight who were naïve to therapy were retained for further investigation. Perfusion was performed 5-42.5 s after contrast, followed by parenchymal and portal venous phases. Blood flow (BF), blood volume (BV), and permeability surface area product (PS) were calculated using deconvolution algorithms. Patients were categorized as responders or non-responders per RECIST 1.1. Perfusion variables with AUC ≥ 0.70 in differentiating responders from non-responders were retained. Logistic regression was used to assess associations between baseline perfusion variables and response.
RESULTS: 18 of 28 patients showed favorable response to therapy. Baseline heterogeneity variables in tumor max ROI were higher in non-responders than responders [median BF coefficient of variation (CV) 0.91 vs. 0.51 respectively, odds ratio (OR) 6.8 per one standard deviation (1-SD) increase, P = 0.047; median PS CV 1.6 vs. 0.68, OR 3.9 per 1-SD increase, P = 0.047; and median BV CV 0.75 vs. 0.54, OR = 4.0 per 1-SD increase, P = 0.047]. Baseline BV mean in tumor center was lower in non-responders than responders (median BV mean: 0.74 vs. 2.9 ml/100 g respectively, OR 0.28 per 1-SD increase, P = 0.047).
CONCLUSION: For patients with PDAC receiving neoadjuvant therapy, lower and more heterogeneous perfusion parameters correlated with an unfavorable response to therapy. Such quantitative information can be acquired utilizing a comprehensive protocol interleaving perfusion CT acquisition with standard of care multiphase CT scans using a single contrast injection, which could be used to identify surgical candidates and predict outcome.
引用
- O'Malley, Cox, Soloff, et al. CT perfusion as a potential biomarker for pancreatic ductal adenocarcinoma during routine staging and restaging. Abdom Radiol (NY). 2022. PMID: 35972550. doi:10.1007/s00261-022-03638-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。